Abstract

A REVIEW: FORMULATION AND IN-VITRO EVALUATION OF SOLID LIPID NANOPARTICLES CONTAINING LEVOSULPIRIDE

Vinod D. Usnale*, Rohit D. Usnale, R.R. More, Dr. Jyotiram Sawale, Dr. Reenu Yadav, Dr. Jitendra Malviya

.

Abstract

Objectives: The current study's objectives are to create Levosulpirideloaded solid lipid nanoparticles (SLNs) to enhance the bioavailable portion of the medicine (often around 30% orally), decrease side effects, and minimize dosage and frequency. Methods: Preformulation investigations on levosulpiride included examinations of its physical characteristics, melting point, assay, calibration curve, FTIR analysis, and DSC analysis. The drug's calibration curve was created in phosphate buffer with a pH of 6.8. To make SLNs, the lipid phase of two lipids (stearic acid and palmitic acid) was employed. In order to create 16 formulations (8 for each lipid, SF1-SF8 and PF1-PF8), the factororial design (23) method was used. The solvent evaporation process was used to create levosulpiride SLNs, which were then homogenized. Results: Particle size analysis, zeta potential analysis, in vitro drug release, and drug release kinetics were used to describe the optimized formulations. By using FTIR, DSC, and TEM analyses, the drug-excipient interaction in the improved formulation was identified. Conclusion: The formulations SF1 (which contains stearic acid) and PF1 (which contains palimitic acid) were found to be better formulations among their groups with a regulated drug release after a period of 24 hours based on evaluation parameters.

Keywords: Levosulpiride, Homogenization, Lipid, Nanoparticle, Assay, Calibration curve.